Acceleron Pharma Inc:
Developing TGF-beta superfamily therapeutics to treat serious and rare diseases. XLRN recently received US FDA approval with partner BMS for REBLOZYL (luspatercept-aamt) for its beta-thalassemia indication and has a PDUFA target action date of April 4th, 2020 for its MDS indication. The companies have multiple Ph2 and Ph3 trials ongoing for chronic anemia in additional patient populations of MDS and beta-thalassemia, as well as myelofibrosis. In addition to hematology, XLRN is advancing its pulmonary franchise with two Ph 2 studies in pulmonary arterial hypertension, as well as a neuromuscular program in Charcot-Marie-Tooth disease. The company expects to report topline results from Ph2 clinical trials in PAH (sotatercept) and CMT (ACE-083) in Q1 2020.
US - New England
Phase III, Phase l or ll
128 Sidney Street
Cambridge, MA 02139
Top 10 Holders of Acceleron Pharma Inc
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by